Topical NSAID Cream Being Tested in Clinical Trial

Transdel Pharmaceuticals, Inc.'s topical NSAID cream, Ketotransdel® (a form of Ketoprofen), is currently being tested in a phase 3 clinical trial. Ketotransdel® uses the patented proprietary Transdel™ drug delivery system. This cream is for the treatment of acute pain and is applied directly to the skin. It has been shown to relieve inflammation and provide an analgesic effect.

All medications come with the risk of side-effects. Some of the (often dangerous) side-effects that are known to be associated with NSAID tablets are gastrointestinal, renal and cardiovascular problems. The use of this cream may minimize the risk of these side-effects. According to THIS Therapeutics Daily article:

...over one hundred thousand patients are hospitalized each year due to orally administered NSAID-related gastro-intestinal (GI) complications. That is because when one takes a pill, it passes from the GI tract into the bloodstream and organs, exposing one to cardiovascular, renal, and hepatic systemic effects.

Medications applied to the skin may still expose the bloodstream and organs to side-effects and complications. However, the exposure is much less than if used orally. The U.S. Food and Drug Administration's (FDA) Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) provides additional information on this type of medication and it's side-effects.

If all goes well in the clinical trials, Ketotransdel® may be the first FDA-approved topical NSAID cream. To read the article on this click HERE. And click HERE for Transdel Pharmaceutical's product page.

Cymbalta Approved For Fibromyalgia Treatment

Cymbalta (Duloxetine) has just been approved to treat Fibromyalgia. Until now, there was only one medication, Lyrica (Pregabalin), approved to treat this illness.

In addition to the side effects of Cymbalta, Medpage Today warns:

Duloxetine should not be taken by patients who are using or have recently used a monoamine oxidase inhibitor, patients taking thioridazine (Mellaril) or patients with uncontrolled glaucoma. Severe and sometimes fatal liver problems have been reported among patients taking duloxetine. Duloxetine may increase the risk of hemorrhage among patients taking NSAIDs, aspirin, or other blood thinners.

Cymbalta is also approved for Major Depressive Disorder, the pain caused by Diabetic Peripheral Neuropathy and Generalized Anxiety Disorder.

Migraine and Fibromyalgia are often comorbid. Other illnesses comorbid with Migraine include but are not limited to Thyroid Disease, Temporomandibular Disorders, Depression, Anxiety, Epilepsy, Hypertension, and Stroke.